BidaskClub upgraded shares of Sientra (NASDAQ:SIEN) from a buy rating to a strong-buy rating in a research report released on Wednesday morning.

Other equities research analysts have also recently issued reports about the company. Canaccord Genuity boosted their price target on Sientra from $19.00 to $25.00 and gave the company a buy rating in a research note on Wednesday, August 8th. Zacks Investment Research cut Sientra from a hold rating to a sell rating in a research note on Tuesday, August 7th. Dougherty & Co assumed coverage on Sientra in a research note on Thursday, August 30th. They issued a buy rating and a $31.00 price target for the company. Stephens reiterated a buy rating and issued a $30.00 price target on shares of Sientra in a research note on Thursday, August 9th. Finally, Stifel Nicolaus boosted their price target on Sientra from $21.00 to $25.00 and gave the company a buy rating in a research note on Wednesday, August 8th. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Sientra currently has a consensus rating of Buy and a consensus price target of $22.50.

Shares of NASDAQ:SIEN opened at $25.48 on Wednesday. Sientra has a 12-month low of $8.79 and a 12-month high of $26.79. The company has a market cap of $719.22 million, a PE ratio of -9.04 and a beta of -0.79. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.06 and a quick ratio of 2.63.

Sientra (NASDAQ:SIEN) last issued its quarterly earnings results on Tuesday, August 7th. The medical instruments supplier reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.04). The company had revenue of $17.55 million during the quarter, compared to the consensus estimate of $15.30 million. Sientra had a negative net margin of 131.16% and a negative return on equity of 151.47%. sell-side analysts predict that Sientra will post -2.93 earnings per share for the current fiscal year.

In other Sientra news, CEO Jeffrey M. Nugent sold 1,852 shares of the company’s stock in a transaction on Friday, August 31st. The stock was sold at an average price of $24.90, for a total transaction of $46,114.80. Following the completion of the sale, the chief executive officer now directly owns 297,999 shares in the company, valued at $7,420,175.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 31.00% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. lifted its stake in Sientra by 94.3% during the second quarter. BlackRock Inc. now owns 1,490,587 shares of the medical instruments supplier’s stock worth $29,081,000 after purchasing an additional 723,279 shares during the last quarter. Gilder Gagnon Howe & Co. LLC lifted its stake in Sientra by 29.8% during the second quarter. Gilder Gagnon Howe & Co. LLC now owns 1,373,007 shares of the medical instruments supplier’s stock worth $26,787,000 after purchasing an additional 315,408 shares during the last quarter. Cannell Capital LLC lifted its stake in Sientra by 15.8% during the first quarter. Cannell Capital LLC now owns 1,158,485 shares of the medical instruments supplier’s stock worth $11,191,000 after purchasing an additional 158,058 shares during the last quarter. Janus Henderson Group PLC bought a new stake in Sientra during the second quarter worth $20,375,000. Finally, Millennium Management LLC lifted its stake in Sientra by 93.4% during the second quarter. Millennium Management LLC now owns 858,206 shares of the medical instruments supplier’s stock worth $16,744,000 after purchasing an additional 414,418 shares during the last quarter. Hedge funds and other institutional investors own 89.21% of the company’s stock.

Sientra Company Profile

Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.

Recommended Story: New Google Finance Tool and Screening Stocks

Analyst Recommendations for Sientra (NASDAQ:SIEN)

Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.